MDVN
MDVN Articles
Stock markets. Equity markets opened sharply higher this morning before falling into negative territory before the ISM and factory order reports were released. The ISM index came in lower than...
Published:
Last Updated:
Medivation, Inc. (NASDAQ: MDVN) is today’s darling in biotech and emerging pharmaceuticals. It and partner Astellas in Japan showed very positive data on its prostate cancer drug candidate. Its...
Published:
Active traders and day traders have many stocks to choose from this Thursday morning. We are tracking news and moves in shares of Aeropostale, Inc. (NYSE: ARO), Dendreon Corporation (NASDAQ:...
Published:
These are some of the top movers in the world of BioHealth investing. It is usual that drug companies and biotech stocks have major volatility around news and these are examples of that today. ...
Published:
We have compiled this morning’s key stocks on the move based on news. These are some of the key stocks being watched and traded by day traders and active traders. There is a more detailed...
Published:
These are the top ten analyst calls we have seen in upgrades, downgrades, and initiations from Wall Street research calls this Thursday morning: BB&T Corp. (NYSE: BBT) Raised to Outperform at...
Published:
Last Updated:
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down...
Published:
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009. At BioHealthInvestor.com we compiled a...
Published:
Acorda Therapeutics inc. (NASDAQ: ACOR) showed late stage trial results on its drug candidate Fampridine-SR for treating multiple sclerosis. This data showed that Fampridine, which is designed to...
Published:
Some new data is helping two small biotech stocks today at the Alzheimer’s Association International Conference on Prevention of Dementia in Washington, DC. The latest figure showed 26.6 million...
Published:
Last Updated:
(ADLR) Adolor said a complete response to the POI ‘Approvable’ Letter now targeted for 3Q 2007.(ALXN) Alexion Pharm says studies show efficacy and safety of it’s Soliris in broad population of...
Published: